Delic Holdings Corp. Provides January 2022 Corporate Update
January 2022 Corporate Update Delic Holdings Corp. (DELC) announced that it plans to more than
January 13, 2022
January 2022 Corporate Update Delic Holdings Corp. (DELC) announced that it plans to more than
atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for PCN-101 R-ketamine Program atai
Filament Health (FH) received Health Canada approval for a psilocybin microdosing study on 100 patients
The McQuade Centre for Strategic Research and Development (MSRD), a subsidiary of Otsuka Pharmaceutical (one
MindBio Therapeutics is aiming to develop a “smart drug delivery technology” that can use patient
Compass Pathways’ (CMPS) early psilocybin research was published in The Journal of Psychopharmacology this week. The
Novamind Signs Definitive Agreement to Acquire Arizona-based Clinics Novamind (NM) is planning to acquire two Arizona-based
HAVN Life Enters Into Definitive Agreement to Acquire Spore Life Sciences Inc. HAVN Life (HAVN) entered
Maya Health Raises $4.3 Million to Decentralize Psychedelic Medicine Research Maya Health raised $4.3M to
MINDCURE Announces Certification of HIPAA Compliance, Bringing iSTRYM Closer to Commercial Deployment in the Second
New Filing Challenges Compass Pathways’ Infamous Patent on Synthetic Psilocybin COMPASS Pathways’ (CMPS) patent for
Doseology Prepares to Expand Mushroom Production by Hiring Dr. Wellman-Labadie to Oversee Planned Research and
atai Life Sciences launches TryptageniX to further expand atai’s robust intellectual property portfolio and strengthen
Analyst Sees Huge Upside for These 2 “Strong Buy” Psychedelic Stocks An analyst at H.C.
Mycotopia and Ei.Ventures sign LOI to Explore Merger and Formation of PSLY.COM, a $360 Million
Delic Launches Industry’s First Family Support & Education Program at Ketamine Wellness Centers (KWC) Nationwide
Way2Grow (W2G) Biopharma Corp. Receives Health Canada Approval Notice for Construction of a Controlled Substances
Mycotopia Therapies Announces Plan to Develop Psychedelic Sublingual Tablet to Help Treat Depression Mycotopia Therapies
Allied Corp Progresses Towards Clinical Phase I Trial for Psilonex™ RX Psilocybin Pharma Drug Allied
Origin Therapeutics Portfolio Company TripSitter Expands to Eight Additional States TripSitter Clinic Corp. now offers
PharmaTher Enters into Research Collaboration Agreement with Revive Therapeutics for Development of Psilocybin Microneedle Patch
Mydecine Reports Successful Synthesis of Novel Tryptamine Improving the Pharmaceutical Properties of Psilocin Using an
Cybin Announces Launch of EMBARK Psychedelic Facilitator Training Program Cybin (CYBN) is sending therapists on
MYND Life Sciences Signs Agreement to Acquire Rights for the Use of Psychedelics to Treat